|

BGB-16673 Clinical Trials

5 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Pipeline

Phase 3: 2Phase 1/2: 3

Top Sponsors

  • BeOne Medicines4
  • BeiGene1

Indications

  • Cancer5
  • B-cell Malignancy3
  • Chronic Lymphocytic Leukemia3
  • Waldenström Macroglobulinemia2
  • Small Lymphocytic Lymphoma2

Birmingham, Alabama2 trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Alabama At Birmingham Hospital

Phase 3

Other1 trial

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2

Phoenix, Arizona1 trial

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Jonesboro, Arkansas1 trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.